Cleared Traditional

K920198 - GLYCOMAT HAEMOGLOBIN ANALYSER

K920198 is an FDA 510(k) clearance for GLYCOMAT HAEMOGLOBIN ANALYSER, manufactured by Drew Scientific , Ltd.. The device is a Class 2 Hematology device with product code LCP cleared through the Traditional 510(k) pathway after a 188-day FDA review.

K920198 · Drew Scientific , Ltd. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1992
Decision
188d
Days
Class 2
Risk

K920198 is an FDA 510(k) clearance for the GLYCOMAT HAEMOGLOBIN ANALYSER. Classified as Assay, Glycosylated Hemoglobin (product code LCP), Class II - Special Controls.

Submitted by Drew Scientific , Ltd. (London W4 4ph Uk, GB). The FDA issued a Cleared decision on July 21, 1992 after a review of 188 days - an extended review cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7470 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all Drew Scientific , Ltd. devices

FDA 510(k) Submission Details - K920198

510(k) Number K920198 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 15, 1992
Decision Date July 21, 1992
Days to Decision 188 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
75d slower than avg
Panel avg: 113d · This submission: 188d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LCP Device Classification - Class 2, Special Controls

Product Code LCP Assay, Glycosylated Hemoglobin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7470
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - LCP Assay, Glycosylated Hemoglobin

All 203
Devices cleared under the same product code (LCP) and FDA review panel - the closest regulatory comparables to K920198.
MODIFICATION COLUMNMATE
K920820 · Helena Laboratories · Aug 1992
REFLAB SYSTEM PACK LIQUID FRUCTOSAMINE REAGENT
K920397 · Medical Analysis Systems, Inc. · Aug 1992
POINTE 750 GLYCOMETER
K920449 · Pointe Scientific, Inc., · Jul 1992
COLUMNMATE II
K921676 · Helena Laboratories · Jul 1992
GLYCO-TEK AFFINITY COLUMN KIT
K921305 · Helena Laboratories · Jun 1992
FRUCTOSAMINE ABG21 TEST SYSTEM
K913614 · Boehringer Mannheim Corp. · Dec 1991